Lowest-Rated StocksLowest-RatedNASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free PTCT Stock Alerts $29.44 +1.48 (+5.29%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$27.91▼$29.8550-Day Range$24.15▼$31.9552-Week Range$17.53▼$59.84Volume434,068 shsAverage Volume914,947 shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice Target$33.53 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get PTC Therapeutics alerts: Email Address PTC Therapeutics MarketRank™ Stock AnalysisAnalyst RatingReduce1.85 Rating ScoreUpside/Downside13.9% Upside$33.53 Price TargetShort InterestBearish14.21% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment0.48Based on 3 Articles This WeekInsider TradingSelling Shares$821,819 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.95) to ($5.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector486th out of 939 stocksPharmaceutical Preparations Industry228th out of 435 stocks 1.9 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.85, and is based on 3 buy ratings, 5 hold ratings, and 5 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.53, PTC Therapeutics has a forecasted upside of 13.9% from its current price of $29.44.Amount of Analyst CoveragePTC Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.21% of the outstanding shares of PTC Therapeutics have been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in PTC Therapeutics has recently decreased by 4.47%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePTC Therapeutics has received a 67.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Glucocorticoids", "Clinical research services for infectious diseases", and "Neuromuscular disorders medication" products. See details.Environmental SustainabilityThe Environmental Impact score for PTC Therapeutics is -1.38. Previous Next 1.9 News and Social Media Coverage News SentimentPTC Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PTC Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $821,819.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of PTC Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($5.95) to ($5.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About PTC Therapeutics Stock (NASDAQ:PTCT)PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Read More PTCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTCT Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comJefferies Financial Group Increases PTC Therapeutics (NASDAQ:PTCT) Price Target to $35.00March 22, 2024 | americanbankingnews.comJefferies Financial Group Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $35.00March 28, 2024 | Huge Alerts (Ad)Trending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! March 19, 2024 | markets.businessinsider.comBuy Rating for PTC Therapeutics Bolstered by Positive Regulatory Prospects and Gene Therapy AdvancesMarch 19, 2024 | markets.businessinsider.comPTC Therapeutics Gains After Announcement Of Key Regulatory UpdatesMarch 19, 2024 | finanznachrichten.dePTC Therapeutics, Inc.: PTC Therapeutics Provides Key Regulatory UpdatesMarch 19, 2024 | markets.businessinsider.comPTC Therapeutics Submits BLA To FDA For Upstaza - Quick FactsMarch 19, 2024 | finance.yahoo.comPTC Therapeutics Provides Key Regulatory UpdatesMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 7, 2024 | markets.businessinsider.comPTC Therapeutics: Navigating Challenges and Pursuing Growth Amidst Regulatory HurdlesMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for PTC Therapeutics Amid Promising Regulatory Progress and Market OpportunityMarch 2, 2024 | finance.yahoo.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comPTC Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 1, 2024 | markets.businessinsider.comPTC Therapeutics: Hold Rating Amidst Revenue Downturn and Regulatory HurdlesFebruary 29, 2024 | finance.yahoo.comPTC Therapeutics Inc (PTCT) Reports Robust Revenue Growth and Advances in PipelineFebruary 29, 2024 | prnewswire.comPTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | msn.comPTC Therapeutics Q4 2023 Earnings PreviewFebruary 28, 2024 | investing.comPTC Therapeutics Inc (PTCT)February 27, 2024 | prnewswire.comPTC Therapeutics to Participate at Upcoming Investor ConferencesFebruary 22, 2024 | finance.yahoo.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 18, 2024 | finance.yahoo.comPTCT Jun 2024 10.000 putFebruary 18, 2024 | finance.yahoo.comPTCT Mar 2024 19.000 putFebruary 15, 2024 | finance.yahoo.comPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | prnewswire.comPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | finance.yahoo.comWill Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should KnowJanuary 26, 2024 | finance.yahoo.comPTC Therapeutics Recovers From An Ugly Fall After European Officials Reject DMD DrugJanuary 26, 2024 | markets.businessinsider.comWilliam Blair Sticks to Its Buy Rating for PTC Therapeutics (PTCT)See More Headlines Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/27/2024Next Earnings (Estimated)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTCT CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year FoundedN/APrice Target and Rating Average Stock Price Target$33.53 High Stock Price Target$55.00 Low Stock Price Target$17.00 Potential Upside/Downside+13.9%Consensus RatingReduce Rating Score (0-4)1.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($8.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-626,600,000.00 Net Margins-66.82% Pretax Margin-74.23% Return on EquityN/A Return on Assets-32.06% Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio1.97 Sales & Book Value Annual Sales$937.82 million Price / Sales2.40 Cash Flow$2.47 per share Price / Cash Flow11.91 Book Value($10.85) per share Price / Book-2.71Miscellaneous Outstanding Shares76,610,000Free Float72,548,000Market Cap$2.26 billion OptionableOptionable Beta0.67 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Matthew B. Klein F.A.C.S. (Age 52)M.D., M.S., CEO & Director Comp: $995.4kDr. Stuart W. Peltz Ph.D. (Age 64)Co-Founder, Senior Consultant & Member of Scientific Advisory Board Comp: $1.54MDr. Allan Steven Jacobson Ph.D. (Age 78)Co-Founder, Chairman of Scientific Advisory Board & Independent Director Comp: $145kDr. Neil Almstead Ph.D. (Age 57)Chief Technical Operations Officer Comp: $829.97kMr. Eric Pauwels (Age 63)Chief Business Officer Comp: $847.67kMr. Pierre Gravier M.S. (Age 38)Chief Financial Officer Ms. Christine Utter (Age 46)Senior VP, Chief Accounting Officer & Head of People Services Comp: $595.54kAlex KaneInvestor Relations OfficerMr. Mark Elliott Boulding (Age 63)Executive VP & Chief Legal Officer Comp: $824.09kMs. Jane BajVice President of Corporate CommunicationsMore ExecutivesKey CompetitorsGalapagosNASDAQ:GLPGVera TherapeuticsNASDAQ:VERAMaravai LifeSciencesNASDAQ:MRVIDyne TherapeuticsNASDAQ:DYNAmphastar PharmaceuticalsNASDAQ:AMPHView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 855,354 shares on 3/11/2024Ownership: 11.488%Wellington Management Group LLPBought 380,415 shares on 3/5/2024Ownership: 12.814%Fisher Asset Management LLCSold 6,359 shares on 3/5/2024Ownership: 0.125%Goldman Sachs Group Inc.Bought 186,608 shares on 3/1/2024Ownership: 0.698%American International Group Inc.Bought 462 shares on 2/28/2024Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions PTCT Stock Analysis - Frequently Asked Questions Should I buy or sell PTC Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 5 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" PTCT shares. View PTCT analyst ratings or view top-rated stocks. What is PTC Therapeutics' stock price target for 2024? 13 analysts have issued 1 year price targets for PTC Therapeutics' stock. Their PTCT share price targets range from $17.00 to $55.00. On average, they predict the company's share price to reach $33.53 in the next year. This suggests a possible upside of 13.9% from the stock's current price. View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts. How have PTCT shares performed in 2024? PTC Therapeutics' stock was trading at $27.56 at the start of the year. Since then, PTCT shares have increased by 6.8% and is now trading at $29.44. View the best growth stocks for 2024 here. When is PTC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our PTCT earnings forecast. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.29 by $0.53. The biopharmaceutical company earned $307.06 million during the quarter, compared to the consensus estimate of $315.90 million. What ETFs hold PTC Therapeutics' stock? ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Motley Fool Small-Cap Growth ETF (TMFS), MFAM Small-Cap Growth ETF (MFMS), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Franklin Genomic Advancements ETF (HELX) and SPDR S&P Biotech ETF (XBI). What guidance has PTC Therapeutics issued on next quarter's earnings? PTC Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $600.0 million-$680.0 million, compared to the consensus revenue estimate of $612.3 million. What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO? 24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD). Who are PTC Therapeutics' major shareholders? PTC Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (12.81%), Vanguard Group Inc. (11.66%), Vanguard Group Inc. (11.49%), RTW Investments LP (9.84%), Armistice Capital LLC (9.10%) and Price T Rowe Associates Inc. MD (1.32%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey and Stuart Walter Peltz. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTCT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.